Hepion Pharmaceuticals In... (HEPA)
Hepion Pharmaceuticals Statistics
Share Statistics
Hepion Pharmaceuticals has 1.08M shares outstanding. The number of shares has increased by -89.82% in one year.
| Shares Outstanding | 1.08M |
| Shares Change (YoY) | -89.82% |
| Shares Change (QoQ) | -89.99% |
| Owned by Institutions (%) | 9.38% |
| Shares Floating | 1.07M |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 65.73K, so 0.62% of the outstanding shares have been sold short.
| Short Interest | 65.73K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 0.62% |
| Short Ratio (days to cover) | 0.92 |
Valuation Ratios
The PE ratio is -13.15 and the forward PE ratio is -0.02. Hepion Pharmaceuticals's PEG ratio is -1.16.
| PE Ratio | -13.15 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 88.35 |
| P/FCF Ratio | -15.73 |
| PEG Ratio | -1.16 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Hepion Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.31, with a Debt / Equity ratio of 0.03.
| Current Ratio | 3.31 |
| Quick Ratio | 3.31 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0 |
| Debt / FCF | -0.01 |
| Interest Coverage | -5118.64 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.22M |
| Employee Count | 22 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -409.02K |
| Effective Tax Rate | 0.83% |
Stock Price Statistics
The stock price has increased by null% in the last 52 weeks. The beta is 1.63, so Hepion Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.63 |
| 52-Week Price Change | null% |
| 50-Day Moving Average | 5.61 |
| 200-Day Moving Average | 28.23 |
| Relative Strength Index (RSI) | 20.49 |
| Average Volume (20 Days) | - |
Income Statement
| Revenue | n/a |
| Gross Profit | -67.13K |
| Operating Income | -48.45M |
| Net Income | -48.93M |
| EBITDA | -49.26M |
| EBIT | -49.33M |
| Earnings Per Share (EPS) | -12.32 |
Balance Sheet
The company has 14.79M in cash and 209.02K in debt, giving a net cash position of 14.58M.
| Cash & Cash Equivalents | 14.79M |
| Total Debt | 209.02K |
| Net Cash | 14.58M |
| Retained Earnings | -224.63M |
| Total Assets | 3.72M |
| Working Capital | 814.33K |
Cash Flow
In the last 12 months, operating cash flow was -40.89M and capital expenditures -14.3K, giving a free cash flow of -40.9M.
| Operating Cash Flow | -40.89M |
| Capital Expenditures | -14.3K |
| Free Cash Flow | -40.9M |
| FCF Per Share | -10.3 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HEPA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
Currently there are no analyst rating for HEPA.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Mar 18, 2025. It was a backward split with a ratio of 1:50.
| Last Split Date | Mar 18, 2025 |
| Split Type | backward |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | -115.54 |
| Piotroski F-Score | 1 |